Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Zanubrutinib Extends Treatment Duration in Acalabrutinib-Intolerant Patients With B-cell Malignancies

January 16th 2023

Patients with B-cell malignancies who were intolerant to acalabrutinib experienced a longer treatment duration when subsequently receiving zanubrutinib.

Duvelisib Wins Orphan Drug Designation for PTCL in Europe

January 10th 2023

The European Commission has issued an orphan drug designation to duvelisib for the treatment of adult patients with peripheral T-cell lymphoma.

FDA Grants Orphan Drug Designation to LP-284 for Mantle Cell Lymphoma

January 9th 2023

The FDA has granted an orphan drug designation to LP-284, a novel small-molecule, next-generation acylfulvene, for the treatment of mantle cell lymphoma

Dr. Sauter on Key Considerations for Posttransplant Pembrolizumab in T-cell NHL

January 4th 2023

Craig Sauter, MD, discusses important considerations regarding the use of pembrolizumab after autologous stem cell transplant in T-cell non-Hodgkin lymphoma.

Glofitamab Plus R-CHOP Displays Tolerable Safety Profile in Treatment-Naïve DLBCL

January 3rd 2023

Max S. Topp, MD, highlights the rationale for studying bispecific antibodies in newly diagnosed diffuse large B-cell lymphoma, how the safety profile of glofitamab plus R-CHOP contributes to its potential for outpatient administration, and where future directions with this research may lead.

Waldenström Macroglobulinemia Treatment Moves Away From Chemotherapy

January 2nd 2023

The past decade has been a time of great progress in the research of Waldenström macroglobulinemia and the care of patients with the rare form of non-Hodgkin lymphoma.

For Staudt, a Keen Eye Sparks Opportunities to Dig Deeper

December 31st 2022

Driven by his twin passions for music and science, Louis M. Staudt, MD, PhD, has made a career out of reading between the notes.

Japan Approves Second-line Axi-cel for LBCL

December 23rd 2022

Japan’s Ministry of Health, Labor and Welfare has approved axicabtagene ciloleucel for the initial treatment of patients with relapsed/refractory large B-cell lymphoma, including diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, transformed follicular lymphoma, and high-grade B-cell lymphoma.

FDA Approves Mosunetuzumab for Relapsed/Refractory Follicular Lymphoma

December 23rd 2022

The FDA has approved mosunetuzumab-axgb (Lunsumio) for the treatment of adult patients with relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy.

Lenalidomide/Rituximab Regimens Show Encouraging Responses in Relapsed/Refractory Follicular Lymphoma, But Slow Accrual Axes Study

December 21st 2022

The regimen of lenalidomide in combination with rituximab with bendamustine are effective therapies for relapsed/refractory follicular lymphoma, with high rates of overall and complete metabolic response by PET, according to data from the randomized phase 2 HOVON110/Rebel trial.

Glofitamab Induces 39% CR Rate in Relapsed/Refractory DLBCL

December 20th 2022

Glofitamab, an investigational CD20xCD3 T-cell engaging bispecific antibody, demonstrated promising results in patients with relapsed/refractory diffuse large B-cell lymphoma who received at least 2 prior lines of therapy.

Dr. Burke on the Underrepresentation of Elderly Patients in Clinical Trials for Lymphoma

December 19th 2022

John M. Burke, MD, discusses the underrepresentation of elderly patients in clinical trials for lymphoma.

Dr. Sauter on Pembrolizumab After Stem Cell Transplant in T-Cell NHL

December 19th 2022

Craig Sauter, MD, discusses the investigation of pembrolizumab given after stem cell transplant in T-cell non-Hodgkin lymphoma.

Dr. Leslie on the 3-Year Follow-Up of the ZUMA-5 Trial in R/R iNHL

December 19th 2022

Lori A. Leslie, MD, discusses the 3-year follow-up data of the phase 2 ZUMA-5 trial in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Tisagenlecleucel Shows Promise in Relapsed/Refractory Aggressive B-Cell NHL and Comorbidities in Real-World Setting

December 15th 2022

Tisagenlecleucel elicited durable efficacy and a favorable long-term safety profile in the real-world setting of patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Dr Topp on the Efficacy of Glofitamab Plus R-CHOP in Previously Untreated DLBCL

December 12th 2022

Max S. Topp, MD, discusses the efficacy of the combination of glofitamab plus R-CHOP from a phase 1 trial done in previously untreated patients with diffuse large B-cell lymphoma.

Unpacking Data in Multiple Myeloma, Non-Hodgkin Lymphoma, and GVHD: Drs Noopur Raje, Joshua Brody, and Ryotaro Nakamura

December 12th 2022

In this episode, OncLive® speaks with Dr. Noopur Raje on developments in multiple myeloma, Dr. Ryotaro Nakamura on data related to graft-vs-host disease, and Dr. Joshua Brody on the latest in non-Hodgkin lymphoma.

Mosunetuzumab Elicits Long-Term Responses in Relapsed/Refractory Follicular Lymphoma

December 12th 2022

Mosunetuzumab demonstrated durable responses and a low rate of adverse events linked with treatment discontinuation in patients with relapsed/refractory follicular lymphoma, according to an updated analysis of the pivotal phase 2 GO29781 study.

Dr Abramson on the Efficacy of Second-line Liso-cel Vs SOC in Relapsed/Refractory LBCL

December 12th 2022

Jeremy Abramson, MD, discusses the efficacy data of second-line lisocabtagene maraleucel vs standard-of-care salvage chemotherapy followed by autologous stem cell transplant from the phase 3 TRANSFORM trial done in patients with relapsed/refractory large B-cell lymphoma.

Liso-Cel Second-Line Superiority to Standard of Care Confirmed in LBCL

December 12th 2022

Second-line treatment with lisocabtagene maraleucel (liso-cel; Breyanzi) reduced the risk of an event occurring by 64.4% compared with standard-of-care chemoimmunotherapy induction and autologous stem cell transplantation for patients with high-risk relapsed/refractory large B-cell lymphoma.